Treatment of Thin Basement Membrane Nephropathy with Hypertension, Proteinuria, or Renal Impairment

Many patients with thin basement membrane nephropathy (TBMN) have a benign, stable course. However, when hypertension, proteinuria, or renal impairment develops, the clinical picture changes significantly and active management is warranted.

Individuals with TBMN should be assessed at presentation for poor prognostic indicators. Hypertension, proteinuria, and renal impairment are each risk factors for progression to end-stage renal failure. When any of these features are present, specialist management by a nephrologist is indicated.

Treatment approach (partial)

The evidence-based first-line approach for TBMN with these features includes an ACE inhibitor as a core component of management — aimed at delaying the onset of renal failure. The complete regimen, monitoring parameters, and follow-up protocol are available in the full structured document.

Instant Access to Structured Evidence-Based Regimens

References

Individuals with TBMN should be assessed at presentation for poor prognostic indicators (hypertension, proteinuria, renal impairment).

However, some individuals develop hypertension, proteinuria, or renal impairment, which are all risk factors for progression to end-stage renal failure.

Those with these features should be managed by a nephrologist, and treatment should include an ACE inhibitor to delay the onset of renal failure.

DOI: 10.1681/ASN.2012020148

View source ↗